소세포폐암(SCLC) 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)
Global Small Cell Lung Cancer (SCLC) Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034
상품코드:1969952
리서치사:Value Market Research
발행일:2026년 02월
페이지 정보:영문 171 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
소세포폐암(SCLC) 치료제 시장 규모는 2025년 187억 8,000만 달러에서 2026-2034년 CAGR 10.34%로 성장하여 2034년에는 455억 3,000만 달러에 달할 것으로 예측됩니다.
세계 소세포폐암(SCLC) 치료제 시장은 특히 흡연자 및 고위험군을 중심으로 전 세계 폐암 발병률 증가로 인해 성장하고 있습니다. 소세포폐암은 공격성이 강한 암종으로 즉각적이고 집중적인 치료가 필요한 암종입니다. 암 조기발견에 대한 인식 개선과 진단기술의 발전이 치료 도입률 향상에 기여하고 있습니다.
주요 성장 요인으로는 면역요법, 표적치료제, 병용요법의 개발이 꼽힙니다. 제약사들은 생존율 향상과 부작용 감소를 위한 연구개발에 많은 투자를 하고 있습니다. 임상시험의 확대와 새로운 약물의 규제 당국의 승인으로 시장 성장이 가속화되고 있습니다. 또한, 암 연구에 대한 정부의 지원적 자금 지원으로 SCLC 치료 분야의 혁신이 강화되고 있습니다.
향후 몇 년 동안 소세포폐암 치료제 시장은 개인 맞춤형 치료 접근법과 정밀 종양학의 혜택을 받을 것으로 예측됩니다. 바이오마커 검사의 발전으로 보다 효과적인 치료법을 선택할 수 있게 되었습니다. 신흥 시장에서도 첨단 암 치료제에 대한 접근성이 개선되면서 새로운 성장 기회가 창출되고 있습니다. 지속적인 혁신과 세계 암에 대한 인식이 높아지면서 시장 전망은 여전히 매우 긍정적입니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 소세포폐암(SCLC) 치료제 시장 : 치료 유형별
제5장 세계의 소세포폐암(SCLC) 치료제 시장 : 투여 경로별
제6장 세계의 소세포폐암(SCLC) 치료제 시장 : 최종사용자별
제7장 세계의 소세포폐암(SCLC) 치료제 시장 : 유통 채널별
제8장 세계의 소세포폐암(SCLC) 치료제 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
LSH
영문 목차
영문목차
The Small Cell Lung Cancer (SCLC) Therapeutics Market size is expected to reach USD 45.53 Billion in 2034 from USD 18.78 Billion (2025) growing at a CAGR of 10.34% during 2026-2034.
The Global Small Cell Lung Cancer (SCLC) Therapeutics Market is growing due to the rising prevalence of lung cancer worldwide, particularly among smokers and high-risk populations. Small cell lung cancer is an aggressive form of cancer that requires immediate and intensive treatment. Increased awareness about early cancer detection and advancements in diagnostic techniques are contributing to higher treatment adoption rates.
Major growth drivers include the development of immunotherapies, targeted therapies, and combination treatment regimens. Pharmaceutical companies are investing heavily in research to improve survival rates and reduce side effects. Expanding clinical trials and regulatory approvals for novel drugs are accelerating market growth. Additionally, supportive government funding for cancer research is strengthening innovation in the SCLC treatment landscape.
In the coming years, the SCLC therapeutics market is expected to benefit from personalized treatment approaches and precision oncology. Advancements in biomarker testing will enable more effective therapy selection. Emerging markets are also improving access to advanced cancer care, creating new growth opportunities. With continuous innovation and increasing global cancer awareness, the market outlook remains highly positive.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Treatment Type
Chemotherapy
Targeted Therapy
Others
By Route of Administration
Intravenous
Others
By End-Users
Hospitals
Homecare
Speciality Centres
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
COMPANIES PROFILED
F HoffmannLa Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, Bayer AG, Lilly, Merck Co Inc, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, Clovis Oncology, Johnson Johnson Private Limited
We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Treatment Type
4.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Route Of Administration
5.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY END-USERS 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast End-users
6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Speciality Centres Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
7.1. Market Analysis, Insights and Forecast Distribution Channel
7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.2.1 By Treatment Type
8.2.2 By Route Of Administration
8.2.3 By End-users
8.2.4 By Distribution Channel
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.3.1 By Treatment Type
8.3.2 By Route Of Administration
8.3.3 By End-users
8.3.4 By Distribution Channel
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.4.1 By Treatment Type
8.4.2 By Route Of Administration
8.4.3 By End-users
8.4.4 By Distribution Channel
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.5.1 By Treatment Type
8.5.2 By Route Of Administration
8.5.3 By End-users
8.5.4 By Distribution Channel
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.6.1 By Treatment Type
8.6.2 By Route Of Administration
8.6.3 By End-users
8.6.4 By Distribution Channel
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL SMALL CELL LUNG CANCER (SCLC) THERAPEUTICS INDUSTRY
